Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Five Cancers Added  to List of Smoking-Related Diseases

July 1, 2004
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 13 No 7
Volume 13
Issue 7

WASHINGTON-The 2004 US Surgeon General’s report on the health risks of smoking adds five cancers to the list of diseases caused by cigarettes-acute myeloid leukemia, and stomach, pancreatic, cervical, and kidney cancers. Other newly

WASHINGTON—The 2004 US Surgeon General’s report on the health risks of smoking adds five cancers to the list of diseases caused by cigarettes—acute myeloid leukemia, and stomach, pancreatic, cervical, and kidney cancers. Other newly listed diseases are abdominal aortic aneurysm, cataracts, periodontitis, and pneumonia.

Published 40 years after the first Surgeon General’s report on smoking and health, which documented the evidence that cigarettes cause cancer of the lung and larynx in men and chronic bronchitis, Health Consequences of Smoking concludes that cigarettes cause disease in almost every organ, at every stage of life.

"In addition to cancer, cardiovascular, and respiratory diseases, and reproductive effects, the 2004 report documents many other damaging effects of smoking," said Surgeon General Richard H. Carmona, MD. The report estimates that 440,000 Americans die each year from smoking-related diseases and notes that smokers reduce their life expectancy by 13.2 years for males and 14.5 years for females. Beginning with the 2004 report, the Surgeon General’s office will indicate the strength of the evidence supporting a causal link between cigarette smoking and disease by using four categories. The cancers in each category are:

■ Sufficient to infer a causal relationship: lung, laryngeal, oral cavity and pharyngeal, esophageal, pancreatic, bladder and kidney, cervical, and gastric cancers, and acute myeloid leukemia.

■  Suggestive but not sufficient to infer a causal relationship: noncardia gastric, colorectal, and liver cancers.

■  Inadequate to infer the presence or absence of a causal relationship: ovarian.

■  Suggestive of no causal relationship: prostate, adult brain, and breast cancers.

The report omitted several cancers—lymphomas and multiple myeloma, and cancers of the skin, bone, and testicles—because they have not been linked to smoking. It also found that "the evidence is sufficient to infer that current smoking reduces the risk of endometrial cancer in postmenopausal women."

Major Conclusions

Health Consequences of Smoking is the first comprehensive assessment since 1990 of the evidence that indicts active cigarette smoking as a hazard to health. "We’ve known for decades that smoking is bad for your health, but this report shows that it is even worse," Dr. Carmona said. The report reached several major conclusions about cigarettes in addition to listing the new diseases attributed to smoking as a cause:

■  Smoking harms nearly every organ of the body, causing many diseases and reducing the health of people who smoke in general.

■  Quitting smoking has immediate as well as long-term benefits, reducing the risk of diseases caused by smoking and improving health in general.

■ Smoking cigarettes with lower machine-measured yields of tar and nicotine provides no clear benefit to health.

Changes in Smoking

The report notes that significant changes have occurred in cigarette smoking in the United States in the 4 decades since then-Surgeon General Luther Terry, MD, released his groundbreaking report on smoking and health. Among them:

■  There has been a broad reduction in society’s acceptance of smoking, which accompanied the growing awareness of tobacco’s dangers.

■  Per capita adult consumption of cigarettes has dropped from its peak of 4,345 annually in 1963 to 1,979 in 2002.

■  The number of former smokers today is greater than the number of current smokers.

■ Cigarette smoking was once a rite of passage for most teens. Today, only about half of high school seniors have ever smoked a cigarette, and about one in four is a current smoker.

The report calls for a sustained effort against smoking, a comprehensive approach to reducing tobacco use, and continued scientific research to address a number of tobacco-related health issues.

Such factors as smoking in motion pictures, the enormous advertising and promotional efforts of cigarette companies, and the belief by some that the smoking problem has been solved support the need to continue antismoking efforts, particularly among children and adolescents, the Surgeon General said.

Finally, the report emphasizes the need for research that further delineates the adverse health effects of tobacco use, improves the efficiency of tobacco surveillance and epidemiology, devises strategies to eliminate tobacco-related health disparities, and provides better prevention and treatment of addiction.

Articles in this issue

Long-Term Raloxifene Reduces Breast Ca Risk
Five Cancers Added  to List of Smoking-Related Diseases
Weekly Paclitaxel Superior to Conventional Schedule in Metastatic Breast Cancer Patients
Autologous Vaccine Delays TTP in Renal Cell Cancer
Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Related Content
Advertisement

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma

Russ Conroy
October 29th 2025
Article

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.


The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Tim Cortese
October 27th 2025
Article

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

Related Content
Advertisement

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma

Russ Conroy
October 29th 2025
Article

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.


The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Tim Cortese
October 27th 2025
Article

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.